Health‐related quality of life · people with primary sclerosing cholangitis
1 finding from 1 review
Liver transplantation · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes liver transplantation compared with placebo (very low certainty).
1 finding from 1 review
Malignancy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cholangiocarcinoma · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes cholangiocarcinoma compared with placebo (very low certainty).
1 finding from 1 review
Colorectal cancer · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term mortality · people with hereditary haemochromatosis
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
All‐cause mortality · people with hereditary haemochromatosis
1 finding from 1 review
Serious adverse events · people with hereditary haemochromatosis
1 finding from 1 review
Health‐related quality of life EQ‐VAS. Scale from: 0 to 100. · people with hereditary haemochromatosis
1 finding from 1 review
Health‐related quality of life beyond one year · people with hereditary haemochromatosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether methotrexate plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review
All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes mortality compared with lactitol (very low certainty).
1 finding from 1 review